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ABSTRACT
In this study, profiles of epidermal growth factor re-
ceptor (EGFR) and Kirsten ras sarcoma (KRAS) mutations 
and response to erlotinib therapy have been investigated in 
patients with non-small cell lung cancer (NSCLC). DNA 
from 300 patients with NSCLC was extracted from paraf-fin-
embedded tissues. After the extracted DNA was sequenced 
by pyrosequencing method, a total of 97 (32.0%) patients 
out of 300 were detected to carry an EGFR mutation and 75 
(25.0%) patients out of 300 carried a KRAS mutation; 20 
(6.6%) patients were detected to carry both of EGFR and 
KRAS mutations. The EGFR mutations were found to be 
statistically significant in female patients (48.0 women vs. 
28.0% men, non smokers (49.0 vs. 26.0%) and adenocarci-
noma (37.8 vs. squamous 26.8%). The overall rate of survival 
in patients receiving erlotinib therapy than in patients who did 
not. In patients without the KRAS mutation, the median over-
all survival rate was 161 ± 30 weeks with erlotinib therapy 
and 90 ± 13 weeks in patients without erlotinib therapy. In 
patients having KRAS mutation, the median overall survival 
was 98 ± 16 weeks with erlotinib therapy and 34 ± 16 weeks 
with no erlotinib therapy. In our study, we once again demon-
strated that the presence of these mutations affected response 
to erlotinib therapy. The KRAS mutations negatively affected 
survival rate with and without erlotinib therapy.
Keywords: Erlotinib therapy; Epidermal growth 
factor receptor (EGFR); Kirsten ras sarcoma (KRAS); 
Non-small cell lung cancer (NSCLC).
INTRODUCTION
Lung cancer is one of the main leading causes of cancer 
death, and the most common cancer after prostate and breast 
cancers, in respect to prevalence [1]. The 5-year overall 
survival is 15.0% in patients with non-small cell lung cancer 
(NSCLC) [1]. Overall survival rates increase with surgical, 
chemotherapy and radiotherapy treatments in early stages 
of the cancer [2]. Recently, immunotherapy and molecular 
targeted therapy have been used to treat cancer patients. 
Erlotinib and gefitinib, which are the inhibitors of epidermal 
growth factor receptor (EGFR) tyrosine kinases are molecu-
lar targeted agents. These agents have been used to inhibit 
certain EGFR tyrosine kinase mutations. Both of them can 
pass through the phospholipid membrane into the cell, and 
these agents compete with adenosine triphosphate (ATP) to 
bind the ATP binding pocket of EGFR. The EGFR, a trans-
membrane glycoprotein of 170 kDa consisting 1186 amino 
acids, is localized in the 7q12 chromosome region. It is 
known that the EGFR receptor has mutations in the tyrosine 
kinase region of 18-21 exons in NSCLC cells and correlate 
therapy response. These EGFR mutations are more common 
in Asian, Caucasian and non smoking women [4]. K-ras, a 
downstream protein, becomes constantly active as a result 
of EGFR auto-phosphorylation. The Kirsten ras sarcoma 
(KRAS) gene belongs to Ras gene family and homolog of 
Kristen rat sarcoma viral oncogene [5-8]. It is localized at the 
chromosome 12 (12q12.1) region and consists of six exons 
transcribed as a small guanosine triphosphatease (GTPase) 
consists of 21k Da and 189 amino acids [5,7]. Codons 12 
and 13 have GTPase-acting proteins (GTPs) binding site 
in the KRAS gene. Codon 61 is the switch II region that 
regulates Ras protein. Mutations at codons 12, 13 and 61 
prevent GTP hydrolysis causing K-ras protein constantly 
active situation. Studies have shown that NSCLC patients 
ORIGINAL ARTICLE
Bereitgestellt von  Pamukkale University | Heruntergeladen  08.11.19 12:19   UTC
22
KRAS IS PROGNOSTIC FACTOR IN NSCLC
with KRAS mutations have lower survival rates than those 
without KRAS mutations [6].
In our study, we investigated the frequency of EGFR 
and KRAS mutations and effects of anti-EGFR tyrosine ki-
nase inhibitors treatment in Turkish NSCLC patients. This 
is the first large-scale study that investigates EGFR and 
KRAS mutations in 300 patients with NSCLC in Turkey.
MATERIALS AND METHODS
Patients. This study was performed in paraffin-em-
bedded tissues of 300 NSCLC patients who attended the 
Medical Oncology Department, Pamukkale University, 
Denizli, Turkey, Medical Oncology Department, Antalya 
Education Research Hospital, Antalya, Turkey and the 
Medical Oncology Department, Afyon Kocatepe Univer-
sity, Afyon, Turkey, between 2011 and 2014. DNA was 
extracted from paraffin-embedded tissues using QIamp 
DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany, 
its purity was checked spectrophotometrically and stored 
at –20 °C. Clinical features of patients are given in Table 1.
Pyrosequencing Method. The extracted DNA was 
sequenced by pyrosequencing, a method which gives effec-
tive with as little as 15 ng DNA. This method is based on 
a real time non electrophoretic system. Pyrosequencing is 
more cost-effective when compared to the dideoxy Sanger 
method. Pyrosequencing is more reliable and effective at 
determining EGFR mutations than the classic sequencing 
method [9]. Polymerase chain reaction (PCR) reaction 
composed of 20 pmol of each primer, 0.2 mmol each of 
deoxy-nucleotide triphosphates, 1.5 mmol/L MgCl2 and 
1.25 U of FastStart Taq DNA polymerase (Qiagen GmbH) 
as total final volume of 50 µL. The PCR method consisted 
of an initial denaturation step at 95 °C for 15 min., fol-
lowed by 42 cycles at 95 °C for 20 seconds, 54 °C for 30 
seconds, 72 °C for 20 seconds, and a final extension step 
at 72 °C for 5 min. The PCR products (10 µL) were ana-
lyzed by electrophoresis on a 3.0% agarose gel to confirm 
successful amplification.
After validation of the PCR products on the gel, 40 
µL of the products were bound to streptavidin Sepha-
rose HP (GE Healthcare, Waukesha, WI, USA), purified, 
washed, and denatured using a 0.2 mol/L sodium hydrox-
ide solution, and washed again. Subsequently, 0.3 µmol/L 
pyrose-quencing primers were annealed to the purified 
single-stranded PCR products, and the pyrosequencing was 
performed on a PyroMark ID system (Qiagen GmbH), ac-
Table 1. Clinicopathological characteristics of the patients.
Characteristics Patients (n = 300) (%)
Age:
     ≤62 years
     ≥62 years
148 (49.3)
152 (50.7)
Gender:
     males
     females
238 (50.7)
  62 (20.7)
Smoking habit:
     smoker
     never smoked
233 (74.3)
  77 (25.7)
Histological type:
     adenocarcinoma
     squamous
     other
228 (76.0)
  62 (20.7)
  10 (3.3)
Stage:
     early (I; II; IIIA)
     advanced (IIIB; IV)
  70 (23.3)
230 (76.7)
Table 2. Detailed clinicopathological characteristics of patients with EGFR and KRAS mutations.
Characteristics Patients EGFR Mutations (32.33%)
KRAS Mutations 
(25.0%)
EGFR and KRAS Mutations 
(6.6%)
(n=300) [+] (n=97) [–] (n=203) [+] (n=75) [–] (n=225) [+] (n=20) [–] (n=280)
Age:
     ≤62 years
     ≥62 years
148
152
50 (32.9%)
47 (31.8%)
102 (67.1%)
101 (68.2%)
32 (21.1%)
43 (29.1%)
120 (78.9%)
105 (70.9%)
  7 (4.6%)
13 (8.8%)
145 (95.4%)
135 (91.2%)
Gender:
     males
     females
238
  62
67 (28.2%)
30 (48.3%)a
171 (71.8%)
  32 (51.7%)
63 (26.5%)
12 (19.4%)
174 (73.5%)
  50 (80.6%)
16 (6.7%)
  4 (6.5%)
222 (93.3%)
  58 (93.5%)
Smoking habit:
     smoker
     never smoked
233
  77
59 (26.5%)
38 (49.4%)a
164 (73.5%)
  39 (50.6%)
58 (26.0%)
17 (22.0%)
165 (74.0%)
  60 (78.0%)
11 (4.9%)
  9 (11.6)
212 (88.4%)
  68 (88.4%)
Histological type:
     adenocarcinoma
     squamous
     other
228
  62
  10
77 (33.7%)a
13 (21.0%)
  7 (70.0%)
151 (66.3%)
  49 (79.0%)
    3 (30.0%)
55 (24.1%)
18 (29.0%)
  2 (20.0%)
173 (75.9%)
  44 (71.0%)
    8 (80.0%)
16 (7.0%)
  2 (3.2%)
  2 (20.0%)
212 (93.0%)
  60 (96.8%)
    8 (80.0%)
Stage:
     early (I; II; IIIA)
     advanced (IIIB; IV)
  70
230
18 (25.7%)
79 (34.3%)
  52 (74.3%)
151 (65.7%)
16 (22.8%)
59 (25.6%)
  54 (77.2%)
171 (74.4%)
  2 (2.8%)
18 (7.8%)
  68 (97.2%)
212 (92.2%)
a Found to be statistically significant.
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cording to the manufacturer’s instructions and analyzed in 
the AQ mode of the PyroMark (Qiagen GmbH) software.
Statistical Analyses. All statistical analyses were 
done using the Statistical Package for the Social Sciences 
(SPSS) version 17.0 (SPSS® IBM Corporation, Armonk, 
NY, USA). For descriptive analyses, the χ2 and t-tests were 
performed. Progression-free survival and overall survival 
analyses, according to EGFR and KRAS mutations’ status 
were done using the Kaplan Meier Method and estimating 
the survival difference with the use of long rank test. A 
value of p <0.05 was accepted to be statistically significant.
RESULTS
Patient Profiles. We conducted this study on par-
affin-embedded tissues of 300 consecutive patients with 
NSCLC from January 2010 through January 2014. In the 
300 patients with NSCLC, 230 (76.7%) patients had ad-
vanced disease, 62 (20.7%) of these patients were female, 
238 (79.3%) were male. Histopathologically, there were 
62 squamous and 228 adenocarcinoma NSCLC patients. 
The median age of the patients was 62 (range 37-82), 233 
(74.3%) had a history of smoking. The patient character-
istics are summarized in Table 1.
EGFR Mutations Profiles. We detected EGFR muta-
tions in 97 patients out of 300 patients, 30 of which were 
female and 67 were male patients. Histopathologically, 
13 were squamous type 77 adenocarcinoma, while seven 
were in other subtypes. In terms of age, 50 patients were 
over 62 years old, 47 patients were less than 62, and 59 
of them are smokers. The EGFR mutations were found 
to be statistically significant in females, non smokers and 
adenocarcinoma patients. Eighteen patients were in early 
stages (I-IIIA), while 79 patients were in advanced stages 
(IIIB-IV), considering progression [9] (Table 2). We de-
tected 53.5% EGFR mutations in exon 19 [Table 3(A)].
Table 3. (A) Types of EGFR mutations in Turkish NSCLC patients. 
Mutation Exon Nucleotide Number Amino Acid Changes Mutation
Point mutation 18 2155 (G>T) G719C   1 (0.8%)
Point mutation 18 2134 (G>A) G719S   3 (2.5%)
Point mutation 18 2155 (G>A) G719A   9 (7.6%)
Deletion 19 235-2249del (GGA ATT AAG AGA AGC) delE746-A750 39 (33.4%)
Del/Ins 19 2235-2252del (GGA ATT AAG AGA AGC insCA) L747-6751insP 10 (8.5%)
Del/Ins 19 2235-2252del (GGA ATT AAG AGA AGC insAAT) delE746-T751insI   5 (4.2%)
Del/Ins 19 2235-2258del (GGA ATT AAG AGA AGC insAAT CCA) delE746-A750insIP   1 (0.8%)
Del/Ins 19 2235-2249del (GGA ATT AAG AGA AGC insAGA) delL747-P753insS   3 (2.5%)
Del/Ins 19 2235-2258del (GGA ATT AAG AGA AGC insAAT) delE746-A750insI   3 (2.5%)
Del/Ins 19 2235-2258del (GGA ATT AAG AGA AGC insCCA) delA746-A750insP   1 (0.8%)
Del/Ins 19 2235-2258del (GGA AAT AAG AGA AGC insCAA) delL747-T751insQ   1 (0.8%)
Point mutation 20 2369 (C>T) T790M   3 (2.5%)
Point mutation 21 2573 (T>G) L858R 10 (8.5%)
Point mutation 21 2582 (T>A) L861Q 29 (24.6%)
Del/Ins: deletions and insertions.
Table 3. (B) Types of KRAS mutations in Turkish NSCLC patients.
Mutation Types Codon Nucleotide Number Amino Acid Changes Mutations
Point mutation 12   34 (G>A) G12S 10 (12.7%)
Point mutation 12   34 (G>T) G12C   8 (10.1%)
Point mutation 12   35 (G>A) G12D   6 (6.7%)
Point mutation 12   35 (G>T) G12V 20 (25.2%)
Point mutation 12   35 (G>A) G12A   1 (1.3%)
Point mutation 13   37 (G>A) G13D   1 (1.3%)
Point mutation 61 182 (A>G) Q61R 18 (22.8%)
Point mutation 61 183 (A>C) Q61H 15 (19.0%)
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KRAS Mutation Profiles. Seventy-five of 300 pa-
tients have KRAS mutations, 12 of which were females, 
63 were males. Histopathologically, 18 patients have squa-
mous type NSCLC, while 55 have adenocarcinoma and 
two were in other subtypes. Thirty-two patients were older 
than 62 and 58 patients were smokers. Sixteen patients 
were in early stages and 59 patients were in advanced 
stages of cancer (Table 2). We found no statistically sig-
nificant differences between KRAS mutations and age, 
gender, smoking, stage of the cancer.
We detected both EGFR-KRAS mutations in 20 
patients, four females and 16 male patients. Histopatho-
logically, two of them were squamous, 16 were adenocar-
cinoma and two were in other types. Two were in early 
stage, 18 were in advanced stages, 13 of them were older 
than 62. Eleven of them are smokers, while nine are not. 
Detailed information is given in Table 2.
Survival Rates of Patients with EGFR-KRAS 
Mutations. Fifty-nine patients who had either EGFR 
mutations or both EGFR and KRAS mutations, received 
erlotinib therapy. We showed that survival rates of patients 
who received EGFR-TKI therapy was significantly higher 
than patients with EGFR mutations who did not receive 
erlotinib therapy [Figure 1(A) and 1(B)].
Twenty patients who have EGFR-KRAS mutations 
and were not treated with erlotinib, had the lowest survival 
rate (34 ± 16 weeks) (p 0.0007) [Figure 2(B)]. Patients 
with both mutations and who received erlotinib therapy, 
had a survival rate of 98 ± 16 weeks [Figure 2(B)]. Patients 
who had only the EGFR mutation and were treated with 
erlotinib, had a survival rate of 161 ± 30 weeks [Figure 
2(A)], and those who did not receive erlotinib therapy, had 
a survival rate of 90 ± 13 weeks [Figure 2(A)].
The overall survival rate patients treated with EGFR-
TKI without progression was also found to be significantly 
higher. Patients who were treated with EGFR-TKI: 288 ± 
11 and those who were not: 119 ± 11 weeks (p 0.004) [Fig-
ure 1(A)]. Overall survival rates were 126 ± 11 in patients 
with EGFR mutations and 121 ± 9 weeks in other patients 
(p 0.266) [Figure 1(B)]. We observed, that patients who 
Figure 1. (A) The progression-free survival rate was statistically 
significantly higher in patients carrying EGFR mutations 
receiving EGFR-TKI therapy in comparison to patients having 
no such treatment. (B) The overall survival rate was statistically 
significantly higher in patients carrying EGFR mutations 
receiving EGFR-TKI therapy in comparison to patients having  
no such treatment.
Figure 2. (A) The overall survival rate was statistically 
significantly higher in patients not carrying the KRAS mutations 
receiving EGFR-TKI therapy in comparison to patients having 
no such treatment. (B) The overall survival rate was statistically 
significantly higher in patients carrying the KRAS mutations 
receiving EGFR-TKI therapy in comparison to patients having  
no such treatment.
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have both EGFR and KRAS mutations, have the lowest 
overall survival rate and erlotinib therapy increased the 
survival rate in patients who have both mutations, while 
progression-free survival rates in patients treated with er-
lotinib were 32 ± 5 weeks, these rates were 33 ± 3 weeks 
in patients who were not treated with erlotinib (p 0.755). 
KRAS mutation 100 ± 4, without mutation 131 ± 11 weeks, 
p 0.038, and without a progression survival rate was not 
statistically significant (KRAS mutations 31 ± 5, without 
KRAS mutation 33 ± 3 weeks, p 0.0807).
DISCUSSION
Non-small cell lung cancer has different subtypes, 
mainly adenocarcinoma, squamous and other subtypes. 
Of these, adenocarcinoma is seen more often in patients 
with NSCLC [10-13]. Previous studies that showed cor-
relation can be found in literature regarding to the subtypes 
of NSCLC in the Turkish population [9,14]. In this study, 
we found 76.0% adenocarcinoma, 20.7% squamous, 3.3% 
other subtypes in 300 patients. The distribution of gender 
has been reported in the literature as: in East Asian com-
munities 54.0-65.0% males, 35.0-46.0% females [10], 
in England 55.0% males, 45.0% females [1], in America 
58.0% males 42.0% females [1]. Two previous studies 
performed in the Turkish population, found 85.0% males 
and 15.0% females by Unal et al. [14], 75.0% males and 
25.0% females by Akca et al. [9]. Our results showed a 
similar gender distribution (Table 2). It has been reported 
that EGFR mutation rates range between 12.2 and 50.0% 
in East Asia communities [10,15]. Recently, population 
studies have shown that European and American popula-
tion have the lowest EGFR mutation rates, 6.0-16.0% and 
15.0-20.0%, respectively, in the world [11,12].
We detected EGFR mutations in 33.0% of all 300 
patients and 84.0% of EGFR mutation-carrying patients 
had adenocarcinoma. Previous studies also showed similar 
results, 66.0 and 81.0% EGFR mutation rates, respectively 
[9,14]. In our study, we found EGFR mutations in 48.0% 
female patients and in 28.0% male patients. This result 
is similar to previous reports that female patients who 
had NSCLC have higher EGFR mutations [10-13]. Re-
garding smoking habits, patients who do not smoke have 
more EGFR mutations [9-15]. In our study, we detected 
EGFR mutations in 49.0% of non smoking patients and in 
28.0% of the smoking patients (Table 2). In the literature, 
EGFR mutations are seen more often in non smokers and 
female Asian patients [10]. Mutation rate also increases 
with advanced stages of NSCLC cancer (IIIB-IV) [10-13]. 
In our study, similar results were obtained in 18.6% early 
stage and 81.4% advanced stage in NSCLC patients with 
EGFR mutations.
The KRAS mutation rates in NSCLC patients were 
reported as 2.3-9.4% in East Asian populations, 11.0-
29.0% in North America, 12.0-31.0% in Europe, 25.0% 
in Mexico, 12.0% in Columbia and 12.0% in Peru [10-
12]. In our research, we found 20.8% patients had KRAS 
mutations (Table 2). We detected 65.0% KRAS mutations 
in codons 12 and 13 and 35.0% in codon 64 [Table 3(B)].
We also found that 6.6% of the patients carry both 
EGFR and KRAS mutations (Table 2). In the literature, 
this rate varied between 1.0 and 15.0% [10-12]. This is 
the first study in the Turkish population showing KRAS 
mutations and erlotinib therapy in NSCLC patients.
Fifty-nine of 97 patients with EGFR mutations were 
treated with EGFR-TKI agent (erlotinib). The average 
overall survival rates are 146 ± 22 weeks in EGFR-TKI 
treated patients and 84 ± 12 weeks in untreated patients. 
Similar results were published in the literature that erlo-
tinib therapy increases overall survival [16] [Figure 1(B)].
The effect of EGFR-TKI treatment on a patient’s 
survival without progression was found to be statistically 
significant. Erlotinib-treated patients’ survival rate was 288 
± 11 weeks and 119 ± 11 weeks in untreated patients. This 
result is in accordance with the literature [16]. EGFR-TKI 
treatment provided longer survival rates in patients carry-
ing only EGFR mutations compared to the patients with 
both mutations [Figure 2(B)]. We report that the overall 
survival rates are 34 ± 16 weeks in patients with KRAS-
EGFR mutations and 98 ± 16 weeks in EGFR mutations 
without KRAS mutations in erlotinib-treated patients. 
Thus, the longest overall survival rates were observed in 
patients with EGFR but without KRAS mutations, and 
the lowest overall survival rates were found in patient 
with EGFR and KRAS mutations in EGFR-TKI-treated 
patients. Therefore, this indicated that KRAS is a prog-
nostic factor for NSCLC.
The mutations on the KRAS gene constantly activate 
K-ras protein, which in turn triggers cancer cell prolifera-
tion via the rapidly accelerated fibrosarcoma/mitogen-ac-
tivated protein kinase kinase/extracellular signal regulated 
kinase (RAF/MEK/ERK) pathway, resulting in ERK tran-
scriptional factor. Mutated K-ras also activates the phos-
po-inositide 3-kinase/phosphoinositide-dependent kinase/
protein kinase B (PI3K/PDK/AKT) and tuberous sclerosis 
complex 1/Ras homologue enriched in brain/mammalian 
target of rapamycin complex 1 (TSC-1/RHEB/mTORC1) 
pathways, which have a role in invasion and metastasis 
in cancer cells [17]. Our research showed that additional 
KRAS mutations are a strong parameter for prognosis. The 
KRAS mutations negatively affect survival rate with and 
without erlotinib therapy [18]. This result suggests that 
KRAS mutation analyses should be routinely performed 
together with EGFR mutation analyses in NSCLC patients.
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